Delivery Order SPE2DB20D2001-SPE2DB25FPNND
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $5,758.57 firm fixed-price delivery order on August 14, 2025, for Mounjaro 2.5 mg/0.5 mL pen injections, with an ultimate completion date of August 15, 2025. The contract, issued without set-aside designation, represents a competitively awarded procurement executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Mounjaro 7.5 mg/0.5 mL pen injections valued at $10,119.18. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors on September 5, 2025. This competitively awarded, non-set-aside contract has a ceiling value of $3,069.11 and is structured as a firm fixed price delivery order with an ultimate completion date of September 8, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Mounjaro 10 mg/0.5 ml pen injections valued at $7,989.68. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 12, 2025, with performance taking place at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract carries no set-aside designation, reflecting the contractor's demonstrated capability to compete in...
- The Defense Logistics Agency awarded a $21,011.11 delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Mounjaro 10 mg/0.5 ml pen injectors, with a completion date of September 9, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a single delivery order under AmerisourceBergen's larger indefinite delivery vehicle with DLA Troop Support Medical. The order will be fulfilled from the company's facility in...
- The Defense Logistics Agency awarded a $56,374.53 firm fixed price delivery order to AmerisourceBergen Drug Corp for Mounjaro 5 mg/0.5 ml pen injectables on August 27, 2025, with performance expected to conclude by August 28, 2025. This non-set-aside contract will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 prime...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Mounjaro 7.5 mg/0.5 ml pen injections with a ceiling value of $20,300.82. This is a firm fixed-price delivery order with no set-aside designation, classified as a competitive award. The order is scheduled for ultimate completion by August 8, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major...
- The Defense Logistics Agency awarded a $3,069.43 delivery order to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 ml pen injections with an ultimate completion date of June 2, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's broader pharmaceutical supply agreements with DLA. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $19,091.85 delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors with an ultimate completion date of September 8, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Mounjaro 2.5 mg/0.5 mL pen injectors valued at $7,226.22 with a firm fixed price structure. The contract, awarded on September 16, 2025, with an ultimate completion date of September 17, 2025, represents a non-competitive set-aside delivery against AmerisourceBergen's existing indefinite delivery contract vehicle. Performance will occur at the company's corporate office location in Conshohocken,...
- SPE2DB20D2001Indefinite Delivery Contract
- SPE2DB20D2001-SPE2DB25FPNNDDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $21,079.75 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 ml pen injections on August 21, 2025, with completion targeted for August 22, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award to this major pharmaceutical distributor. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion prime vehicle extending through December 2026 that provides comprehensive global pharmaceutical support to military healthcare systems. The IDC enables AmerisourceBergen to supply an extensive range of medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support Defense Health Agency operations and other federal healthcare systems worldwide. Mounjaro is a GLP-1 receptor agonist used for diabetes management, reflecting the company's role in delivering specialty medications critical to military medical readiness.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.1k | 8/21/25 |